FDA stop sign
Pharma

FDA rejects Summit’s PD-1xVEGF ivonescimab in NSCLC

Ivonescimab’s setback has narrowed its potential first-mover advantage as several pharma giants race to advance their own PD-(L)1xVEGF bispecifics.
Angus Liu Nov 15, 2026 7:50am
Genentech Life Doesnt Wait campaign

Genentech celebrates real Hemlibra patients in new videos

Nov 15, 2026 1:00am
AZ

AstraZeneca cuts 600 US sales jobs: Bloomberg

Nov 13, 2026 5:45pm
AZ

AZ's Imfinzi keeps MIBC race against Keytruda hot with FDA nod

Nov 13, 2026 5:40pm
showdown clash versus vs crash lightning fight dispute

The Oral GLP-1 Tracker: Foundayo, Wegovy pill keep climibing

Nov 13, 2026 4:15pm
Silhouette of multiple thumbs ups against the sky

Europe recommends AZ's Baxfendy and Hansoh's Aumseqa

Nov 13, 2026 12:00pm
More News

Teva's 1st R&D day lets CEO bask in innovative drug refresh

Nov 13, 2026 11:16am

Bavarian Nordic’s CFO steps down amid Q3 beat

Nov 13, 2026 11:10am

China's Big Pharma dream meets US crackdown—Fierce Pharma Asia

Nov 13, 2026 8:38am

Novo amps up Wegovy marketing with DJ Khaled partnership

Nov 13, 2026 6:03am